Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for QIAGEN N.V. (QGEN : NYSE)

• Company Description    QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia. Number of Employees: 5,654

• Price / Volume Information    Yesterday's Closing Price: $41.37 Daily Weekly Monthly 20 Day Moving Average: 3,015,821 shares Shares Outstanding: 206.07 (millions) Market Capitalization: $8,525.32 (millions) Beta: 0.64 52 Week High: $57.82 52 Week Low: $32.53 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 6.24% 5.46% 12 Week 19.64% 16.36% Year To Date -12.61% -19.09%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL HULSTERWEG 82 - PL VENLO,P7 5912 NLD ph: 31-77-355-6600 fax: 31-77-355-6658 daniel.wendorff@qiagen.com http://www.qiagen.com

• General Corporate Information    Officers Thierry Bernard - Chief Executive Officer Roland Sackers - Chief Financial Officer Toralf Haag - Supervisory Director Eva Pisa - Supervisory Director Metin Colpan - Supervisory Director Peer Information QIAGEN N.V. (CORR.) QIAGEN N.V. (RSPI) QIAGEN N.V. (CGXP) QIAGEN N.V. (BGEN) QIAGEN N.V. (GTBP) QIAGEN N.V. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N72482156 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 206.07 Most Recent Split Date: 1.00 (0.95:1) Beta: 0.64 Market Capitalization: $8,525.32 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.85% Current Fiscal Quarter EPS Consensus Estimate: $0.63 Indicated Annual Dividend: $0.35 Current Fiscal Year EPS Consensus Estimate: $2.43 Payout Ratio: 0.11 Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: 0.09 Estmated Long-Term EPS Growth Rate: 4.13% Last Dividend Paid: 07/07/2026 - $0.35 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: 17.05 Trailing 12 Months: 17.00 PEG Ratio: 4.13 Price Ratios Price/Book: 2.56 Price/Cash Flow: 12.15 Price / Sales: 4.06 EPS Growth vs. Year Ago Period: -6.73% vs. Previous Quarter: -12.90% Sales Growth vs. Year Ago Period: 1.83% vs. Previous Quarter: -8.90% ROE 06/30/26 - - 03/31/26 - 14.40 12/31/25 - 14.56 ROA 06/30/26 - - 03/31/26 - 8.40 12/31/25 - 8.62 Current Ratio 06/30/26 - - 03/31/26 - 3.21 12/31/25 - 3.90 Quick Ratio 06/30/26 - - 03/31/26 - 2.57 12/31/25 - 3.31 Operating Margin 06/30/26 - - 03/31/26 - 24.47 12/31/25 - 24.97 Net Margin 06/30/26 - - 03/31/26 - 19.16 12/31/25 - 20.33 Pre-Tax Margin 06/30/26 - - 03/31/26 - 21.75 12/31/25 - 23.46 Book Value 06/30/26 - - 03/31/26 - 16.17 12/31/25 - 17.89 Inventory Turnover 06/30/26 - - 03/31/26 - 2.67 12/31/25 - 2.71 Debt-to-Equity 06/30/26 - - 03/31/26 - 0.49 12/31/25 - 0.44 Debt-to-Capital 06/30/26 - - 03/31/26 - 33.08 12/31/25 - 30.45

Powered by Zacks Investment Research ©